Synonyms: example 1 [US10092556B2] | TAS-119 | TAS119 | VIC1911
Compound class:
Synthetic organic
Comment: VIC 1911 (formerly TAS 119) is an oral, small molecule Aurora kinase A-selective inhibitor. It is being progressed by Vitrac Therapeutics for anti-cancer potential.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
VIC-1911 is being evaluated as monotherapy and in combination with the KRAS G12C-targeting drug sotorasib, for efficacy against locally advanced or metastatic KRAS G12C +ve non-small cell lung cancer. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05374538 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | Phase 1 Interventional | Vitrac Therapeutics, LLC |